Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BCAL DiagnosticsASX:BDX +3.57% 3-Year EBITDA Growth Rate is 5.30% as of Dec. 2025, which is at its 10-year median of 5.30. The stock has 3 warning signs investors should review. Among 165 Medical Diagnostics & Research companies, BCAL Diagnostics ranks worse than 55.76% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of BCAL Diagnostics was 5.30% per year. The lowest was 5.30% per year. And the median was 5.30% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
BCAL Diagnostics 3-Year EBITDA Growth Rate Related Terms
ASX:BDX vs TMO, DHR, IDXX: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, BCAL Diagnostics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BCAL Diagnostics 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where BCAL Diagnostics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 5.30% mean?
BCAL Diagnostics (ASX:BDX) has a 3-Year EBITDA Growth Rate of 5.30% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BCAL Diagnostics and its competitors. This is near median its historical median of 5.30. Over the past decade, BCAL Diagnostics' 3-Year EBITDA Growth Rate has ranged from 5.30 to 5.30. According to the industry distribution chart, BCAL Diagnostics ranks #92 out of 165 companies in the Medical Diagnostics & Research industry, placing it in the top 55.8%.
Is BCAL Diagnostics' 3-Year EBITDA Growth Rate too high?
BCAL Diagnostics' current 3-Year EBITDA Growth Rate of 5.30% is near median its 10-year median of 5.30. Over the past 10 years, this metric has ranged from a low of 5.30 to a high of 5.30. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.00. BCAL Diagnostics' value of 5.30% is 51.8% below this industry median. Based on the distribution chart, BCAL Diagnostics ranks #92 out of 165 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does BCAL Diagnostics' 3-Year EBITDA Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BCAL Diagnostics ranks #92 out of 165 companies for 3-Year EBITDA Growth Rate. This places BCAL Diagnostics in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.00. BCAL Diagnostics' value of 5.30% is 51.8% below this benchmark. Historically, BCAL Diagnostics' own 3-Year EBITDA Growth Rate has ranged from 5.30 to 5.30 over the past decade. While the company's 10-year median is 5.30 vs. the industry median of 11.00, BCAL Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 165 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BCAL Diagnostics's current 3-Year EBITDA Growth Rate of 5.30% is 51.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for BCAL Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BCAL Diagnostics's current 3-Year EBITDA Growth Rate is 5.30%, which is near median its own 10-year median of 5.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current 3-Year EBITDA Growth Rate of 5.30%. The current 3-Year EBITDA Growth Rate is 5.30%, which is near median its 10-year median of 5.30 and 51.8% below the Medical Diagnostics & Research industry median of 11.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current 3-Year EBITDA Growth Rate is 5.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BDX has been successfully added to your 
